Novel Biomarker for Rheumatoid Arthritis: Serum Peptidylarginine Deiminase 4‐Potentiating Activity in an Anti‐Citrullinated Protein Antibody‐Positive At‐Risk Population
Marta Kaminska, Vijay Joshua, Ewa Bielecka, Tomasz Kantyka, Maja Chrobak, Karin Lundberg, Aase Hensvold, Jan Potempa, Piotr Mydel · 2026
Read Novel Biomarker for Rheumatoid Arthritis: Serum Peptidylarginine Deiminase 4‐Potentiating Activity in an Anti‐Citrullinated Protein Antibody‐Positive At‐Risk Population by Marta Kaminska, Vijay Joshua, Ewa Bielecka, Tomasz Kantyka, Maja Chrobak, Karin Lundberg, Aase Hensvold, Jan Potempa, Piotr Mydel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13183999.txt.
Description
Marta Kaminska and co-authors test a blood marker that may warn of rheumatoid arthritis before joints are hit. Some healthy people carry antibodies tied to the disease, and only some of them go on to develop it. Their 2026 paper studies an enzyme, PAD4, whose activity helps create the targets those antibodies attack, and asks whether serum that boosts the enzyme marks higher risk.
The study followed 267 antibody-positive people in a Swedish risk cohort, of whom 101 developed arthritis over roughly two to five years. Blood that boosted the enzyme was found in 35 people, and a clear share of them went on to develop arthritis. Their rate of progression was higher than in the rest. The authors argue this boosting activity could join known risk factors, such as genes and smoking, in spotting who needs watching most.
Catalog record
| CREATOR | Marta Kaminska, Vijay Joshua, Ewa Bielecka, Tomasz Kantyka, Maja Chrobak, Karin Lundberg, Aase Hensvold, Jan Potempa, Piotr Mydel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |